AstraZeneca plans to invest ₹250 crore to expand its global innovation and technology centre in Chennai, creating 1,300 new roles by 2025 to drive innovation and enhance operations globally.
Coimbatore: AstraZeneca India Private Limited (AZIPL), the global capability centre of AstraZeneca, has announced a significant expansion of its operations in Chennai. The company will invest ₹250 crore ($30 million) to expand its global innovation and technology centre (GITC) in the city, creating approximately 1,300 new jobs by 2025.
The expanded facility was inaugurated on Thursday by TN Minister of Industries TRB Rajaa, British Deputy High Commissioner to India Christina Scott CMG, and AstraZeneca's Vice President for Asia Area Sylvia Varela. This investment marks AstraZeneca's 45th year of presence in India.
The new roles at the expanded GITC will focus on driving innovation, enhancing efficiency, and streamlining operations across the company globally. AstraZeneca aims to leverage cutting-edge technologies such as enterprise platforms, artificial intelligence, machine learning, data science, and supply chain analytics.
Siva Padmanabhan, Managing Director of AZIPL, emphasized the company's commitment to staying ahead in healthcare and pharmaceutical industries. He stated, "We are evolving our technologies constantly so that we can stay ahead of the curve in healthcare and pharmaceutical industries to better serve our patients in countries where we operate."
TN Minister of Industries TRB Rajaa highlighted Chennai's emergence as the GCC capital of India, leading to historical levels of office space absorption and bringing high-quality jobs to the state. The expansion is expected to contribute significantly to the city's growing tech ecosystem.
AstraZeneca's office space at Ramanujan IT City, currently spanning 3.34 lakh sq ft, will expand by about 1.8 lakh sq ft over the next six months. This expansion will make it the company's biggest global capability centre. Including the GITC, AstraZeneca now employs more than 4,000 people in India, further solidifying its presence in the country's pharmaceutical and healthcare sectors.
The expanded facility was inaugurated on Thursday by TN Minister of Industries TRB Rajaa, British Deputy High Commissioner to India Christina Scott CMG, and AstraZeneca's Vice President for Asia Area Sylvia Varela. This investment marks AstraZeneca's 45th year of presence in India.
The new roles at the expanded GITC will focus on driving innovation, enhancing efficiency, and streamlining operations across the company globally. AstraZeneca aims to leverage cutting-edge technologies such as enterprise platforms, artificial intelligence, machine learning, data science, and supply chain analytics.
Siva Padmanabhan, Managing Director of AZIPL, emphasized the company's commitment to staying ahead in healthcare and pharmaceutical industries. He stated, "We are evolving our technologies constantly so that we can stay ahead of the curve in healthcare and pharmaceutical industries to better serve our patients in countries where we operate."
TN Minister of Industries TRB Rajaa highlighted Chennai's emergence as the GCC capital of India, leading to historical levels of office space absorption and bringing high-quality jobs to the state. The expansion is expected to contribute significantly to the city's growing tech ecosystem.
AstraZeneca's office space at Ramanujan IT City, currently spanning 3.34 lakh sq ft, will expand by about 1.8 lakh sq ft over the next six months. This expansion will make it the company's biggest global capability centre. Including the GITC, AstraZeneca now employs more than 4,000 people in India, further solidifying its presence in the country's pharmaceutical and healthcare sectors.